Results 181 to 190 of about 6,916,201 (263)

AARS2‐SIRT5‐Driven DLD K445 Lactylation Promotes Cuproptosis Resistance in Glioblastoma Stem Cells

Advanced Science, EarlyView.
Lactylation of DLD at K445 by AARS2 suppresses PDH complex activity and reduces DLAT lipoylation, thereby conferring cuproptosis resistance in glioblastoma stem cells. SIRT5‐mediated delactylation restores PDH function and enhances cuproptosis sensitivity.
Mingtian Ding, Haibiao Xu, Cen Liu, Yangyin Ding, Shuai Wang, Jun Yin, Tao Fu, Xiao Jiang, Yuning Chen, Hui Luo, Rui Li, Zhengxin Chen, Huibo Wang   +12 more
wiley   +1 more source

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

, 2016
Colorectal cancer (CRC) organoids can be derived from almost all CRC patients and therefore capture the genetic diversity of this disease. We assembled a panel of CRC organoids carrying either wild-type or mutant RAS, as well as normal organoids and ...
van de Wetering, Marc, Clevers, Hans, Gerwen, Bastiaan van, Bernards, René, van der Ven, Marieke, Mertens, Sander, Snippert, Hugo J, Bos, Johannes L, Drost, Jarno, Egan, David A, Verissimo, Carla S, Overmeer, René M, Ponsioen, Bas, Verlaan-Klink, Ingrid, CMM Sectie Molecular Cancer Research, Regenerative Medicine and Stem Cells, CMM Groep Bos, Child Health, CMM Cell Screening Center, CMM Groep Snippert, Hubrecht Institute with UMC, Cancer   +21 more
core  

PLOD1 Catalytic Activity Stabilizes ENO1 by Limiting FBXW7‐dependent Degradation to Promote Glycolysis and TMZ Resistance in Glioblastoma

Advanced Science, EarlyView.
PLOD1 interacts with ENO1 and limits its FBXW7‐dependent ubiquitination and proteasomal degradation through a mechanism requiring PLOD1 catalytic activity. ENO1 stabilization sustains glycolysis, promoting glioblastoma cell proliferation, migration, and temozolomide resistance.
Fen Xue, Dingkong Liang, Xin Chen, Fei Fan, Xiayun He   +4 more
wiley   +1 more source

A Biomimetic Buffering Hydrogel Scaffold for Long-Term Culture of Patient-Derived Tumor Organoids. [PDF]

Adv Healthc Mater
Gusarova E, Ahmadi F, Cruickshank J, Miao Z, Moshkova M, Pilipenko I, Cescon DW, Kumacheva E.   +7 more
europepmc   +1 more source

Orthogonal Light‐ and Enzyme‐Triggered and‐Gate Prodrugs for Senolytic Therapy

Advanced Science, EarlyView.
An orthogonal AND‐gate prodrug platform combines 390 nm near‐UV photocleavage with SA‐β‐gal activation to control payload release in senescent cells. Its modular architecture enables 4‐MU fluorescence, doxorubicin‐mediated cytotoxicity, and ARV‐771‐driven BRD4 degradation, supporting stimulus‐controlled senolytic design in cellular and organoid models.
Mengyang Chang, Kaixue Zhang, Junwei Wang, Fangchao Bi, Zhuoxin Dai, Miao Yang, Ming Liu, Huanzhi Peng, Franklin Zhang, Yuan Guo, Jigang Dai, Quanxing Liu, Wei Wang   +12 more
wiley   +1 more source

Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids. [PDF]

Front Oncol
Zhang F, Wang Y, Zhang X, Bai Y, Zhang L, Wei S.   +5 more
europepmc   +1 more source

Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinoma. [PDF]

Oncol Rep, 2021
Kazama A, Anraku T, Kuroki H, Shirono Y, Murata M, Bilim V, Ugolkov A, Saito K, Tomita Y.   +8 more
europepmc   +1 more source

Mechanism‐Informed Language Modeling and Oxygenated 3D Screening Identify Berberine–Enzalutamide Synergy in Prostate Cancer Models

Advanced Science, EarlyView.
By integrating knowledge‐augmented artificial intelligence with an oxygen‐supplemented 3D screening platform, a synergistic interaction between berberine and enzalutamide is identified. The framework integrates compound mechanisms of action with disease‐relevant signaling context to prioritize candidate combinations and generate testable pathway‐based ...
Chih‐Hui Lo, Katie Shi, Lina Kafadarian, Alexandra Bermudez, Johnny Diaz, Liam Edwards, Yunqi Hong, Ziyi Chen, Hyeonji Hwang, Weihong Yan, Alan Levinson, Robert Damoiseaux, Cho‐Jui Hsieh, Tanya Stoyanova, Andrew S. Goldstein, Neil Y.C. Lin   +15 more
wiley   +1 more source

Patient-Derived Tumor Organoids to Model Cancer Cell Plasticity and Overcome Therapeutic Resistance. [PDF]

Cells
Coppo R, Inoue M.
europepmc   +1 more source

Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging. [PDF]

STAR Protoc, 2022
Larsen BM, Cancino A, Shaxted JM, Salahudeen AA.   +3 more
europepmc   +1 more source